NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...

With the recipient facing extreme breathing difficulty, a heart transplant was the only option left. While his family waited ...

Discover BridgeBio Pharma's groundbreaking patent for treating ATTR cardiomyopathy with Compound 1, showcasing improved patient outcomes and reduced mortality rates.

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, ...

Approximately 7%–13% of patients may have left ventricular outflow tract obstruction caused by basal left ventricular hypercontractility.4 Treatment is supportive and guided by hemodynamics and the ...

Shares of biopharma outfit Edgewise Therapeutics ( EWTX -4.14%) soared more than 50% today, reaching a three-year high ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...